Cyclosphosphamide therapy of medulloblastoma: From the laboratory to the clinic and back again (and again and again)

摘要: Medulloblastoma, the most common malignancy of childhood, was originally shown to be sensitive cyclophosphamide in 1981. We have used combined laboratory and clinical investigations demonstrate synergy vincristine treatment this tumor, therapeutic gain associated with escalation dosage cyclophosphamide, consequence mechanisms underlying resistance medulloblastoma emerging importance neuroaxis as a site relapse medulloblastoma, newer approaches, including intrathecal 4-hydroperoxycyclophosphamide busulfan, treat neuraxis disease. These studies serve paradigm for laboratory-clinical translational research.